Logo image of ABIO

ARCA BIOPHARMA INC (ABIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABIO - US00211Y5069 - Common Stock

2.4 USD
-0.1 (-4%)
Last: 8/30/2024, 8:00:00 PM
2.48 USD
+0.08 (+3.33%)
After Hours: 8/30/2024, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, ABIO scores 3 out of 10 in our fundamental rating. ABIO was compared to 530 industry peers in the Biotechnology industry. ABIO has a great financial health rating, but its profitability evaluates not so good. ABIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABIO has reported negative net income.
ABIO had a negative operating cash flow in the past year.
In the past 5 years ABIO always reported negative net income.
In the past 5 years ABIO always reported negative operating cash flow.
ABIO Yearly Net Income VS EBIT VS OCF VS FCFABIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -21.27%, ABIO is in the better half of the industry, outperforming 77.82% of the companies in the same industry.
The Return On Equity of ABIO (-22.10%) is better than 85.21% of its industry peers.
Industry RankSector Rank
ROA -21.27%
ROE -22.1%
ROIC N/A
ROA(3y)-24.11%
ROA(5y)-31.22%
ROE(3y)-25.36%
ROE(5y)-33.83%
ROIC(3y)N/A
ROIC(5y)N/A
ABIO Yearly ROA, ROE, ROICABIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABIO Yearly Profit, Operating, Gross MarginsABIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, ABIO has more shares outstanding
The number of shares outstanding for ABIO has been increased compared to 5 years ago.
ABIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ABIO Yearly Shares OutstandingABIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
ABIO Yearly Total Debt VS Total AssetsABIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

An Altman-Z score of 8.70 indicates that ABIO is not in any danger for bankruptcy at the moment.
ABIO's Altman-Z score of 8.70 is amongst the best of the industry. ABIO outperforms 84.33% of its industry peers.
ABIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.7
ROIC/WACCN/A
WACCN/A
ABIO Yearly LT Debt VS Equity VS FCFABIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

ABIO has a Current Ratio of 26.61. This indicates that ABIO is financially healthy and has no problem in meeting its short term obligations.
ABIO has a Current ratio of 26.61. This is amongst the best in the industry. ABIO outperforms 95.95% of its industry peers.
ABIO has a Quick Ratio of 26.61. This indicates that ABIO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 26.61, ABIO belongs to the top of the industry, outperforming 95.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 26.61
Quick Ratio 26.61
ABIO Yearly Current Assets VS Current LiabilitesABIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

ABIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.18%.
EPS 1Y (TTM)-13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABIO Yearly EPS VS EstimatesABIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2024 2025 2026 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABIO Price Earnings VS Forward Price EarningsABIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABIO Per share dataABIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

ABIO has a Yearly Dividend Yield of 67.21%, which is a nice return.
In the last 3 months the price of ABIO has falen by -35.14%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
ABIO's Dividend Yield is rather good when compared to the industry average which is at 1.02. ABIO pays more dividend than 99.82% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 1.88, ABIO pays a better dividend.
Industry RankSector Rank
Dividend Yield 67.21%

5.2 History

ABIO is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ABIO Yearly Dividends per shareABIO Yearly Dividends per shareYearly Dividends per share 2024 5 10 15

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ABIO Yearly Income VS Free CF VS DividendABIO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

More info and screens

ARCA BIOPHARMA INC

NASDAQ:ABIO (8/30/2024, 8:00:00 PM)

After market: 2.48 +0.08 (+3.33%)

2.4

-0.1 (-4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2024-07-31/amc
Earnings (Next)10-16 2024-10-16/amc
Inst Owners0.05%
Inst Owner Change0%
Ins Owners61.11%
Ins Owner Change0%
Market Cap34.82M
Revenue(TTM)N/A
Net Income(TTM)-7.20M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 67.21%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB 1.07
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0
BVpS2.24
TBVpS2.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.27%
ROE -22.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.11%
ROA(5y)-31.22%
ROE(3y)-25.36%
ROE(5y)-33.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 26.61
Quick Ratio 26.61
Altman-Z 8.7
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)92.92%
Cap/Depr(5y)95.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-79.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.85%
OCF growth 3YN/A
OCF growth 5YN/A

ARCA BIOPHARMA INC / ABIO FAQ

What is the fundamental rating for ABIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to ABIO.


What is the valuation status of ARCA BIOPHARMA INC (ABIO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ARCA BIOPHARMA INC (ABIO). This can be considered as Overvalued.


Can you provide the profitability details for ARCA BIOPHARMA INC?

ARCA BIOPHARMA INC (ABIO) has a profitability rating of 1 / 10.